An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity
Objectives: To assess serum levels of endothelial monocyte activating polypeptide-II (EMAP-II) in patients with arterial hypertension with and without type 2 diabetes mellitus and obesity.Materials and methods: We examined 41 hypertensive patients with type 2 diabetes, 18 obese hypertensive patients...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2016-11-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://www.omet-endojournals.ru/jour/article/view/7823 |
| _version_ | 1797204579643817984 |
|---|---|
| author | Liliya Mogylnytska Boris Mankovsky |
| author_facet | Liliya Mogylnytska Boris Mankovsky |
| author_sort | Liliya Mogylnytska |
| collection | DOAJ |
| description | Objectives: To assess serum levels of endothelial monocyte activating polypeptide-II (EMAP-II) in patients with arterial hypertension with and without type 2 diabetes mellitus and obesity.Materials and methods: We examined 41 hypertensive patients with type 2 diabetes, 18 obese hypertensive patients without diabetes, 9 non-obese hypertensive patients without diabetes, and 18 healthy control subjects.Results: We found an increased serum level of EMAP-II in hypertensive patients with type 2 diabetes compared to controls (4.86±2.3 and 1.08±0.53 ng/ml respectively, р<0.01), in hypertensive patients with obesity (2.92±1.42 ng/ml) compared to controls, and in non-obese hypertensive patients (2.02±0.33 ng/ml) compared to controls. Also, the levels of EMAP-II significantly correlated with HbA1c, blood glucose, serum insulin levels, HOMA, lipids, and body mass index (р<0.01).Conclusions: The revealed changes could reflect an endothelial dysfunction mostly pronounced in patients with arterial hypertension, type 2 diabetes mellitus and obesity. Hyperglycemia, dyslipidemia, insulin resistance, obesity appear to be significant contributing factors leading to the elevation of EMAP-II. |
| first_indexed | 2024-03-08T09:12:52Z |
| format | Article |
| id | doaj.art-0e064e6ce9de435e9af2acaccbec4e4a |
| institution | Directory Open Access Journal |
| issn | 2071-8713 2306-5524 |
| language | English |
| last_indexed | 2024-04-24T08:37:28Z |
| publishDate | 2016-11-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Ожирение и метаболизм |
| spelling | doaj.art-0e064e6ce9de435e9af2acaccbec4e4a2024-04-16T16:16:10ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242016-11-01133495310.14341/omet2016349-537415An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesityLiliya Mogylnytska0Boris Mankovsky1Khmelnytsky regional hospital, UkraineP.L. Shupyk National Medical Academy of Postgraduate EducationObjectives: To assess serum levels of endothelial monocyte activating polypeptide-II (EMAP-II) in patients with arterial hypertension with and without type 2 diabetes mellitus and obesity.Materials and methods: We examined 41 hypertensive patients with type 2 diabetes, 18 obese hypertensive patients without diabetes, 9 non-obese hypertensive patients without diabetes, and 18 healthy control subjects.Results: We found an increased serum level of EMAP-II in hypertensive patients with type 2 diabetes compared to controls (4.86±2.3 and 1.08±0.53 ng/ml respectively, р<0.01), in hypertensive patients with obesity (2.92±1.42 ng/ml) compared to controls, and in non-obese hypertensive patients (2.02±0.33 ng/ml) compared to controls. Also, the levels of EMAP-II significantly correlated with HbA1c, blood glucose, serum insulin levels, HOMA, lipids, and body mass index (р<0.01).Conclusions: The revealed changes could reflect an endothelial dysfunction mostly pronounced in patients with arterial hypertension, type 2 diabetes mellitus and obesity. Hyperglycemia, dyslipidemia, insulin resistance, obesity appear to be significant contributing factors leading to the elevation of EMAP-II.https://www.omet-endojournals.ru/jour/article/view/7823endothelial monocyte activating polypeptide iiemap-ii, endothelial dysfunctionarterial hypertensiontype 2 diabetesobesity |
| spellingShingle | Liliya Mogylnytska Boris Mankovsky An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity Ожирение и метаболизм endothelial monocyte activating polypeptide ii emap-ii, endothelial dysfunction arterial hypertension type 2 diabetes obesity |
| title | An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity |
| title_full | An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity |
| title_fullStr | An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity |
| title_full_unstemmed | An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity |
| title_short | An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity |
| title_sort | elevated serum level of endothelial monocyte activating polypeptide ii in patients with arterial hypertension with and without type 2 diabetes and obesity |
| topic | endothelial monocyte activating polypeptide ii emap-ii, endothelial dysfunction arterial hypertension type 2 diabetes obesity |
| url | https://www.omet-endojournals.ru/jour/article/view/7823 |
| work_keys_str_mv | AT liliyamogylnytska anelevatedserumlevelofendothelialmonocyteactivatingpolypeptideiiinpatientswitharterialhypertensionwithandwithouttype2diabetesandobesity AT borismankovsky anelevatedserumlevelofendothelialmonocyteactivatingpolypeptideiiinpatientswitharterialhypertensionwithandwithouttype2diabetesandobesity AT liliyamogylnytska elevatedserumlevelofendothelialmonocyteactivatingpolypeptideiiinpatientswitharterialhypertensionwithandwithouttype2diabetesandobesity AT borismankovsky elevatedserumlevelofendothelialmonocyteactivatingpolypeptideiiinpatientswitharterialhypertensionwithandwithouttype2diabetesandobesity |